Gastroenterology

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.

Data presented at ACG 2023 shows a significantly increased risk of infection and hospitalization due to RSV in patients with IBD. An investigator discusses implications during an era of increased vaccine options.

Presented at United European Gastroenterology Week 2023, results of the retrospective study showed ferric maltol was safe for us in pregnant patients with IBD and iron deficiency anemia.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

Post-hoc analysis clarifies efficacy of upadacitinib for patients with moderately to severely active Crohn's disease with a CDAI of 220 or more.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Findings from a systematic review and meta-analysis revealed the pooled incidence rate of cerebrovascular accidents in patients with IBD was greater than in the general population.

Though rare, pediatric colon cancer often presents in advanced stages—emphasizing the need for awareness of risk factors and the opportunities borne from timely intervention.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Screen time ≥2 hours/day at 8 years of age was associated with an increased risk of developing IBD.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

Fibrosis regression was prevalent among 57% of the cohort and was associated with older age and advanced fibrosis at baseline.